News Releases

NYSE Euronext welcomes EOS imaging to its European market
Paris, 16 February 2012 – EOS imaging (FR0011191766 – EOSI), the pioneer in 2D/3D orthopaedic medical imaging, today celebrated its listing on NYSE Euronext in Paris.

The EOS imaging group designs, develops and markets EOS®, a medical imaging system that has revolutionised the care and treatment chain for major bone and joint diseases (hip, knee, spine) and related orthopaedic surgery. Based on the research of Nobel Physics laureate George Charpak, EOS® is the first imaging solution to capture whole-body 2D and 3D images of standing patients using a very low dose of radiation. The group has been authorised to market its system in 30 countries, including the United States (FDA), Canada, Australia and the European Union. Sales totalled €6.9 million in 2011.

EOS imaging was listed through the admission to trading of 11,882,429[1] existing shares and 5,520,000 new shares issued under a Global Offering,[2] including full exercise of the extension clause. The Global Offering raised a total of €37.9 million, which could rise to €41 million if the greenshoe option is fully exercised.
The admission and issue price of EOS imaging shares was set at €6.87, at the high end of the indicative spread. Market capitalisation stood at around €120 million on the day of listing.
“We are delighted to welcome the EOS imaging group to our European market and, in so doing, play an active role in developing its innovative business. This signals the reopening of listings on the Paris market and illustrates our efforts in the past two years to facilitate financing for businesses, particularly the SMEs that create value and jobs,” said Marc Lefèvre, Head of European Coverage at NYSE Euronext.

“Medical technology is one of the world’s fastest growing sectors and offers huge scope for expansion – as investors are well aware. Listing will enable EOS imaging to benefit from the excellent services that NYSE Euronext offers the financial community, and also to diversify its sources of financing as it expands in new geographical regions,” he added.

Marie Meynadier, CEO of EOS imaging, added: “We are very pleased with the success of our public offering. Through listing we have raised the capital we need to step up our international marketing and sales effort and to develop innovative solutions based on the EOS® platform.”

NYSE Euronext                                                                                                   
Caroline Tourrier –
EOS imaging
NewCap. – Financial communications and investor relations
Sophie Boulila / Pierre Laurent –
Alize RP – Press relations
Caroline Carmagnol / Anne-Sophie Cosquéric /    
About NYSE Euronext
NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets - the New York Stock Exchange, NYSE Euronext, NYSE Amex, NYSE Alternext and NYSE Arca - represent one-third of the worlds equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index, and is the only exchange operator in the Fortune 500. For more information, please visit:

About EOS imaging
The EOS imaging group designs, develops and markets EOS®, a revolutionary and patented medical imaging system based on technology that enabled George Charpak to win the Nobel Prize for Physics. The Group has obtained authorisation to market the system in 30 countries, including the United States (FDA), Canada, Australia and the European Union. Thanks to an installed base of 42 sites and more than 150,000 imaging sessions, EOS® is recognised within the international scientific and medical community. The Group posted 2011 sales of €6.9 million and employed 57 people, including an R&D team of 21 engineers, as of 31 December 2011. It has a head office in Paris, a US subsidiary in Cambridge, Massachusetts, and offices in Montreal, Canada and Germany. To learn more, visit: www.eos‐
(1) Includes 278,870 new shares created by the redemption in shares, today, at the admission price, of bonds redeemable in shares issued by EOS imaging.
(2) The Global Offering was made up of an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.